In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are a discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.

, , , ,
doi.org/10.1007/s002590100502, hdl.handle.net/1765/70734
European Journal of Nuclear Medicine
Department of Internal Medicine

Breeman, W., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W., Kooij, P., … Krenning, E. (2001). Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. European Journal of Nuclear Medicine (Vol. 28, pp. 1421–1429). doi:10.1007/s002590100502